Synnovation Therapeutics
Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized for best-in-class pharmacology against validated disease targets. Their pipeline focuses on precision oncologic targets, aiming to improve patient outcomes by addressing limitations of existing treatments. The company's lead program, SNV1521, is a PARP1 inhibitor currently in Phase I studies.
Funding Round: Series A
Funding Amount: $102M
Date: 24-Jan-2024
Investors: Third Rock Ventures, Nextech, Lilly Asia Ventures, Sirona Capital, Cormorant Asset Management
Markets: Biotechnology, Oncology, Pharmaceutical, Life Science, Medical
HQ: Wilmington, Delaware, United States
Founded: 2021
Website: https://www.synnovationtx.com/
LinkedIn: https://www.linkedin.com/company/synnovationtx
Crunchbase: https://www.crunchbase.com/organization/synnovation-therapeutics
Leave a Comment
Comments
No comments yet.